Citizens JMP analyst Jason Butler lowered the firm’s price target on Dynavax (DVAX) to $31 from $33 and keeps an Outperform rating on the shares. Dynavax reported record Q1 net HEPLISAV-B sales, a 36% increase over last year, with total market share increasing by 2%, to 43%, and expects to end 2025 in the top-half of guidance of net HEPLISAV-B sales of $305M-$325M, the analyst tells investors in a research note. New pipeline programs include an H5N1 flu vaccine trial to start this year, plus Lyme disease to be in the clinic in 2027, the firm says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX:
- Dynavax’s Strategic Positioning and Growth Potential Reinforce Buy Rating
- Dynavax Technologies Reports Strong Q1 2025 Results
- Strong Buy Rating for Dynavax Amidst Promising Growth and Market Prospects
- DVAX Upcoming Earnings Report: What to Expect?
- Dynavax shareholder Deep Track files proxy statement
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue